Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Peripheral Th17 immune signature associates with excellent response to anti-PD1/anti-PD-L1 therapy across solid tumors.
Journal: Cancer immunology research
Published: December 17, 2025
Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy.
Journal: Cancer research communications
Published: May 05, 2025
Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures.
Journal: The Journal of clinical investigation
Published: March 17, 2025
Anti-CTLA4 Therapy Leads to Early Expansion of a Peripheral Th17 Population and Induction of Th1 Cytokines.
Journal: Cancer immunology research
Published: October 24, 2024
Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockade.
Journal: Journal for immunotherapy of cancer
Published: October 07, 2024
Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitors.
Journal: Nature communications
Published: May 14, 2024
Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures.
Journal: The Journal of clinical investigation
Published: November 20, 2023
Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma.
Journal: Cancer research communications
Published: February 05, 2023
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
Journal: Journal for immunotherapy of cancer
Published: September 16, 2022
Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab.
Journal: Journal for immunotherapy of cancer
Published: August 15, 2021
A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab.
Journal: Targeted oncology
Published: July 27, 2021
Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma.
Journal: Biomarker research
Published: July 19, 2021
Last Updated: 09/26/2026